CONTE, PIETRO

Nome completo

CONTE, PIETRO

Mostra records

Risultati 1 - 2 di 2 (tempo di esecuzione: 0.006 secondi).

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial

2016-01-01 Dieci, M. V.; Prat, A.; Tagliafico, E.; Paré, L.; Ficarra, G.; Bisagni, G.; Piacentini, F.; Generali, Daniele; Conte, Pietro; Guarneri, V.

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

2016-01-01 Jerusalem, G.; Mariani, G.; Ciruelos, E. M.; Martin, M.; Tjan Heijnen, V. C. G.; Neven, P.; Gavila, J. G.; Michelotti, A.; Montemurro, F.; Generali, Daniele; Simoncini, E.; Lang, I.; Mardiak, J.; Naume, B.; Camozzi, M.; Lorizzo, K.; Bianchetti, S.; Conte, Pietro

Titolo	Data di pubblicazione	Autori	File
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial	1-gen-2016	Dieci, M. V.Prat, A.Tagliafico, E.Paré, L.Ficarra, G.Bisagni, G.Piacentini, F.GENERALI, DANIELECONTE, PIETROGuarneri, V. + -
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)	1-gen-2016	Jerusalem, G.Mariani, G.Ciruelos, E. M.Martin, M.Tjan Heijnen, V. C. G.Neven, P.Gavila, J. G.Michelotti, A.Montemurro, F.GENERALI, DANIELESimoncini, E.Lang, I.Mardiak, J.Naume, B.Camozzi, M.Lorizzo, K.Bianchetti, S.CONTE, PIETRO + -

ArTS Archivio della ricerca di Trieste

CONTE, PIETRO

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)